DDInter781 DDInter1678
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Fosinopril {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Fosinopril {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Fosinopril {u} (Compound) causes {v} (Side Effect) Menstrual disorder
Menstrual disorder {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Fosinopril {u} (Compound) resembles {v} (Compound) Trandolapril
Trandolapril {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Fosinopril {u} (Compound) causes {v} (Side Effect) Peripheral vascular disorder
Peripheral vascular disorder {u} (Side Effect) is caused by {v} (Compound) Fenofibrate
Fenofibrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Fosinopril {u} (Compound) resembles {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Moexipril
Moexipril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} (Compound) downregulates {v} (Gene) CASP10
CASP10 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Fosinopril (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Fosinopril (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Sirolimus (Compound)
Fosinopril (Compound) causes Menstrual disorder (Side Effect) and Menstrual disorder (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Fosinopril (Compound) resembles Trandolapril (Compound) and Trandolapril (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Fosinopril (Compound) causes Peripheral vascular disorder (Side Effect) and Peripheral vascular disorder (Side Effect) is caused by Fenofibrate (Compound) and Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Fosinopril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) downregulates CASP10 (Gene) and CASP10 (Gene) is upregulated by Sirolimus (Compound)